BioSpace News Archive

OraSure Technologies, Inc., announced that its 2021 Annual Meeting of Stockholders will be a completely virtual meeting, conducted as a live webcast beginning at 10:00 a.m. Eastern on Tuesday, May 18, 2021.

Growcentia, Inc., a biotechnology company, announced their entry into the consumer garden market.

Second Sight Medical Products, Inc., a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced two-year results of its Early Feasibility Study of the Orion Visual Cortical Prosthesis.

Data demonstrated that XTX101, a tumor-selective anti-CTLA-4 antibody, and anti-PD-1 combination increased tumor growth inhibition without an increase in toxicity in vivo

Indigo Diabetes N.V., a pioneering developer of medical solutions using nanophotonics, is pleased to announce the appointment of Paul Moraviec as Chairman of its Board of Directors.

C4 Therapeutics, Inc., a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, announced that the Company will participate in the following upcoming investor conferences:

Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Science Translational Medicine has published a foundational preclinical article describing the synergy of avasopasem manganese

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the first quarter 2021 and business highlights, including an update on its progress with fadraciclib and CYC140, Cyclacel’s novel CDK2/9 and PLK1 inhibitors, respectively.

Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the Company”), a global leader in innovations for active healing, today reported financial results for three months ended April 3, 2021.

89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today reported its financial results for the quarter ended March 31, 2021.